Dimitrios Salgkamis, PhD student at Oncology-Pathology Department, Karolinska Institutet, shared a post on LinkedIn:
“In my first visit to the US, I had the privilege of presenting our work at the largest annual conference dedicated to breast cancer – the 2025 San Antonio Breast Cancer Symposium (SABCS 2025), held December 9–12, 2025.
Title of the poster (PS2-08-01):
‘A predictive gene signature for benefit from dose-dense adjuvant chemotherapy in patients with high-risk early breast cancer: results from the PANTHER phase III trial.’
The Abstract was awarded The Margaret Foti Foundation Scholar-in-Training Travel Award.
In brief, we have identified a subgroup of patients that derive greater benefit from tailored dose-dense adjuvant chemotherapy compared to standard dose. This subgroup consisted of 159 patients (33% of the dataset) positive for the dd-Sensitive signature received 13% absolute benefit from tailored dose-dense schedule compared to standard dose.
Special thanks to Michail Sarafidis for the bioinformatic analysis, Alexios Matikas for supervising the project, and the PIs of PANTHER phase III trial Theodoros Foukakis and Jonas Bergh. We now:
Aim to validate our findings in independent cohorts.
Overall, it was an incredible experience to participate and engage with top scientists and talented researchers!
It was even more rewarding to share this journey with my group colleagues Ioannis Zerdes and Kerstin Wimmer making the experience both joyful and personally memorable!”
More posts from SABCS 2025.